35951 |
Oncology |
PD-1 inhibitors for non-small cell lung cancer patients with special i... |
Cancer Med 2020 10.1002/cam4.2868 |
안명주 |
2020 |
35950 |
Immunology |
PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are... |
CELL MOL IMMUNOL 2020 10.1038/s41423-020-0427-6 |
안명주 |
2020 |
35949 |
Oncology |
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation... |
J CLIN ONCOL 2020 10.1200/JCO.19.00457 |
안명주 |
2020 |
35948 |
Oncology |
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Unc... |
J CLIN ONCOL 2020 10.1200/JCO.19.00931 |
안명주 |
2020 |
35947 |
Oncology; Respiratory System |
Osimertinib for Patients With Leptomeningeal Metastases Associated Wit... |
J THORAC ONCOL 2020 10.1016/j.jtho.2019.12.113 |
안명주 |
2020 |
35946 |
Oncology; Pharmacology & Pharmacy |
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lu... |
INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3 |
안명주 |
2020 |
35945 |
Oncology |
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Pa... |
CANCER RES TREAT 2020 10.4143/crt.2019.186 |
안명주 |
2020 |
35944 |
Medicine, Research & Experimental |
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Pa... |
IN VIVO 2020 10.21873/invivo.11920 |
안명주 |
2020 |
35943 |
Oncology |
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lu... |
CANCER RES TREAT 2020 10.4143/crt.2019.200 |
안명주 |
2020 |
35942 |
Oncology |
TATTON: a multi-arm, phase lb trial of osimertinib combined with selum... |
ANN ONCOL 2020 10.1016/j.annonc.2020.01.013 |
안명주 |
2020 |